Connect with us

Business

Moderna says its vaccine candidate has ‘potential’ to confer longer-term immunity – MarketWatch

Published

on

post featured image
ADVERTISEMENT

Moderna Inc. said late Thursday that its COVID-19 vaccine candidate has potential to confer longer-term immunity, and that it expects to have 20 million doses of the trial vaccine at hand in the U.S. this year. Moderna
MRNA,
+9.97%
said that according to a National Institute of Allergy and Infectious Diseases study, participants in an earlier trial stage of the vaccine candidate retained high levels of neutralizing antibodies for three months following their first vaccination (two months following…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
Jobless claims remained at historic highs last week, as Biden inherits the worst job market of any modern president – The Washington Post
post featured image
New Google union ‘concerned’ after a senior A.I. ethics researcher is reportedly locked out of her account – CNBC
post featured image
Ford Shares Surge As Jim Cramer Highlights President Biden’s Electric Vehicle Push – TheStreet